NCT07128472Recruiting
Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira
Source: ClinicalTrials.gov · Last updated 19 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 13 Aug 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 20 Jan 2026
- Lead sponsor
- South Valley University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07128472
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Aug 2025 to the primary completion date, 20 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
- Patients with known genetic disorders affect immune system function.
- Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
- Renal \&Vascular diseases
Other
- Pregnancy and lactation.
- Patients currently undergoing any treatment other than Humira.
- Patients were undergoing any treatment other than Humira in the last 6 months.
- Patients with contraindication to Humira.
Who the study is looking for
- \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qina University hospital, South Valley University Hospital Coordinator of this site? Confirm its status | Qina | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.